skip to Main Content
My Account   Search by Structure    

Welcome to Our New Look!

Welcome to Our New Look! Welcome to Quanta BioDesign's new website! If you are a new visitor to our site, welcome! We are always glad to have new visitors. Quanta BioDesign, Ltd. makes and sells single molecular weight (i.e., monodispersed)…

Read More
Graph showing the relationship of dPEG® linker length in relation to potency and specificity in extracellular drug conjugates.

Extracellular Drug Conjugates Therapeutically Exploit Protein Proximity

Pharmaceutical company Centrose, founded by James R. Prudent, Ph.D., developed a new class of antibody drug conjugates called extracellular drug conjugates. Nature Publishing Group published the research as a open access paper in its Molecular Therapy journal.1 Apart from the interesting and important development of a new class of antibody drug conjugate (ADC), the research also showed how important linker length 2 is to the potency and specificity of the EDC.

Read More
Amphotericin B conjugated to a discrete PEG (dPEG®) linker with a free amine have higher water solubility and lower toxicity than the parent compound.

Amphotericin B+dPEG®: Water-Soluble, Less Toxic, Potent

Amphotericin B conjugated to a discrete PEG (dPEG®) linker with a free amine have higher water solubility and lower toxicity than the parent compound.
Amphotericin B conjugated to a discrete PEG (dPEG®) linker with a free amine has  higher water solubility and lower toxicity than the parent compound. Image used by permission from J. Med. Chem. (2016), 59, 1197-1206, copyright 2016, American Chemical Society.

About Amphotericin B

Structure of Amphotericin B. Used with permission from J. Med. Chem. (2016), 59, 1197-1206, copyright 2016, American Chemical Society.
Figure 1: Structure of Amphotericin B. Image used by permission from J. Med. Chem. (2016), 59, 1197-1206, copyright 2016, American Chemical Society.

Amphotericin B (Figure 1) is the “gold standard” treatment for systemic fungal infections and diseases caused by the parasite Leishmania. Sometimes it is the only effective treatment because drug resistance renders other treatments useless. Systemic fungal infections are an increasingly serious, widespread problem in medicine. Patients with weakened or suppressed immune systems (caused by HIV/AIDS, diabetes, organ transplants, some cancer treatments) are especially at risk. An estimated 1.5-2 million people die each year from systemic fungal infections (1). Despite its “gold standard” label, there are several difficulties with Amphotericin B.

Read More
Back To Top